Groskaufmanis L, Lin P, Kamdar N, Khan A, Peterson MD, Meade M, Mahmoudi E. Racial and ethnic inequities in use of preventive services among privately insured adults with a pediatric-onset disability. Ann Fam Med. 2022 Sep;20(5):430-7. doi: 10.1370/afm.2849
Van Scoy LJ, Miller EL, Snyder B, Wasserman E, Chinchilli VM, Zgierska AE, Rabago D, Lennon CL, Lipnick D, Toyobo O, Ruffin 4th MT, Lennon RP. Knowledge, perceptions, and preferred information sources related to COVID-19 among central Pennsylvania adults early in the pandemic: a mixed methods cross-sectional survey. Ann Fam Med. 2021 Jul;19(4):293-301. doi: 10.1370/afm.2674
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Cheraghi-Sohi S, Hole AR, Mead N, McDonald R, Whalley D, Bower P, Roland M. What patients want from primary care consultations: a discrete choice experiment to identify patients' priorities. Ann Fam Med. 2008 Mar 15;6(2):107-15.